Posted on July 26, 2021 by Sitemaster
As of Friday (July 22), we had received more than 250 responses to our brief survey on research into active surveillance. Most of these are from patients and some from their familial supporters (spouses, partners, etc.). However,we are still interested in getting more input — especially from clinicians, including specialists, generalists, and allied health personnel like urology nurses! … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: active surveillance, AS, research | 2 Comments »
Posted on July 26, 2021 by Sitemaster
Three more upcoming webinars this week will deal with (a) the work-up of men with prostate cancer prostate cancer who progress after first-line therapy (such as surgery, radiation, etc.); (b) whether Gleason 6 disease should really be defined as “prostate cancer”; and (c) an update on the most current information related to the evaluation and management of men with prostate cancer appropriate for active surveillance. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: progression. active, surveillance, webinar | Leave a comment »
Posted on June 23, 2021 by Sitemaster
Three upcoming webinars deal with (a) the diagnosis and work-up of clinically significant forms of localized prostate cancer; (b) handling anxiety and related issues for men on active surveillance (AS); and (c) whether AS is appropriate for African Americans and others of African ethnicity. See below for details. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: education, patient, webinar | 1 Comment »
Posted on June 22, 2021 by Sitemaster
A diverse group of patients, patient advocates, patient spouses/supporters, physicians, and other researchers has come together, with funding support from the Patient Centered Outcomes Research Institute (PCORI), to plan a virtual conference for the fall of 2021. At that conference, we intend to discuss and identify new and evolving opportunities for research into the most appropriate, high-need, high-impact topics affecting the use of active surveillance (AS) for the management of favorable-risk forms of prostate cancer (i.e., low-risk and “favorable” intermediate-risk disease). … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: active, research, surveillance | 5 Comments »
Posted on June 5, 2021 by Sitemaster
As we’ve seen, brachy boost therapy seems to have the best oncological results for men with very high-risk prostate cancer. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Risk, Treatment, Uncategorized | Tagged: ADT, brachy boost, high-risk, hormonal therapy, radiotherapy | 1 Comment »
Posted on May 31, 2021 by Sitemaster
In ,a recent media release, Lantheus Holdings announced that the US Food and Drug Administration (FDA) had approved the imaging agent known as piflufolastat F 18 Injection (also known as Pylarify® or more commonly just “PyL”) as a PSMA-based PET imaging agent for identification of prostate cancer. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: imaging, PET scan, PyL, Pylarify | 16 Comments »
Posted on April 1, 2021 by Sitemaster
According to a recent article in Modern Pathology, a team of researchers at Yale University and at Memorial Sloan-Kettering Cancer Center (MSKCC) have been able to show that an artificial intelligence (AI) system designed and validated at MSKCC could be used to diagnose prostate cancer as either “suspicious” or “not suspicious” based on data from nearly 2,000 slides of prostate tissue acquired at Yale Medicine. … READ MORE …
Filed under: Diagnosis, Risk | Tagged: AI, artificial, biopsy, intelligence, pathology, slide | 4 Comments »
Posted on March 22, 2021 by Sitemaster
As some of our readers will already be aware, Prostate Cancer International has been working in concert with Dr. M. Mihaj Siddiqui at the University of Maryland School of Medicine and the PATIENTS program at the University of Maryland School of Pharmacy to put together a grant request for funding for a program to identify evidence gaps to guide future research on the use of active surveillance to monitor low-risk prostate cancers. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: active, initiative, research, surveillance | 3 Comments »
Posted on March 22, 2021 by Sitemaster
As Howard Wolinsky has been learning over the past few years, not all prostate cancer support groups are “equal” — in the sense that individual support group leaders may be seriously biased by their own personal experiences (which may have occurred many years ago). … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management | Tagged: bias, group, support | 2 Comments »
Posted on March 10, 2021 by Sitemaster
So (in our opinion) the time has come — for a whole bunch of reasons — for actual and potential prostate cancer patients to start asking their urologists about whether they are able to carry out transperineal as opposed to transrectal biopsies. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer | Tagged: benefit, biopsy, risk, transperineal, transrectal | 12 Comments »
Posted on March 1, 2021 by Sitemaster
In February, a group of researchers initiated a major new survey of patient knowledge about active surveillance as an initial management option for men with lower risk forms of prostate cancer. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: active, knowledge, patient, surveillance, survey | Leave a comment »
Posted on February 15, 2021 by Sitemaster
As we have mentioned previously, data on the use of a variety of methods of urine testing in assessment of risk for clinically significant prostate cancer (and therefore the need for a follow-up biopsy) continues to evolve. … READ MORE …
Filed under: Diagnosis, Risk | Tagged: MyProstateScore, risk, test, urine | Leave a comment »
Posted on February 9, 2021 by Sitemaster
The abstract of a presentation to be given by Egan et al. — from the National Institutes of Health (NIH) at Bethesda, MD — at the upcoming, virtual Genitourinary Cancers Symposium has indicated that active surveillance (AS) seems to be a very reasonable option for first-line management for compliant patients initially diagnosed with Grade Group 2 prostate cancer. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: 2, active, grade group, progression, surveillance | 9 Comments »
Posted on February 8, 2021 by Sitemaster
The “best” way to identify clinically significant, localized prostate cancer continues to evolve. But there is still no consensus about what that “best” way might be to do this, let alone any consensus about the detection of “clinically insignificant”, localized prostate cancer. … READ MORE …
Filed under: Diagnosis, Risk | Tagged: biopsy, Diagnosis, MRi-guided, risk, systematic | Leave a comment »
Posted on January 29, 2021 by Sitemaster
Two technologies have come together to allow for a new kind of radiation treatment known as simultaneous integrated boost (SIB), or, more informally, “dose painting.” … READ MORE …
Filed under: Diagnosis, Management, Treatment | Tagged: boost, dose painting, integrated, radiation, SIB, simultaneous | 5 Comments »
